+1 (704) 266-3234

Epilepsy Drugs Market: Global Demand, Growth Potential & Opportunity Outlook 2021

Published on: Jan 1970 | From USD $800 | Published By: DPI RESEARCH | Number Of Pages: 80

Epilepsy Drugs Market is likely to reach nearly USD 5.5 Billion by the year end of 2021.

Market growth can be attributed to factors such as rising incidence of neurological disorders, growing disease awareness, introduction of novel antiepileptic drugs (AEDs), strong government support and initiatives. Moreover, increasing R&D investment and launch of extended-release formulations are further expected to fuel the market growth. However, high cost of patented drugs, concerns over decreasing healthcare costs as part of government austerity measures, particularly in Europe and low accessibility to antiepileptic drugs in low and middle income countries, are likely to restrict the market growth.

Vimpat is the undisputed leading drug of Global Epilepsy Drugs Market. It has a market share of nearly 22% in 2016 and is expected that Vimpat will gain its momentum till the forecasting period. Keppra was the second highest market share taker with more than 19% share in 2016 but the prospect of this drug will change due to the patent expiration in 2018 and its share decline to XX% by 2021. It is expected that Lamictal will be second leading drug with nearly XX% share by 2021. Onfi hold the third highest share of the Epilepsy Drugs market, being followed by Depakine by the year end of 2021.

The research report titled Epilepsy Drugs Market: Global Demand, Growth Potential & Opportunity Outlook 2021 examines the market, competitive landscape and trends of the Global Epilepsy Drug Market. This report analyzes market data and provides a better understanding of Epilepsy Drugs sales value and demand in the Global Market. Market outlook in value terms for the forecasted period for Epilepsy Drugs Market has been detailed in the report. Key trends in terms of collaborations, partnerships and licensing agreements are analysed with details. The report also explores detailed description of growth drivers and inhibitors of the Global Epilpesy Drugs Market.

The report concludes with the profiles of major players in the Epilepsy Drugs Market such as UCB, EISAI, Pfizer, Sanofi and Lundbeck. The major market players are evaluated on various parameters such as company overview and latest development and trends in the Epilepsy Drugs Market


Key Topics Covered in the Report

Worldwide Epilepsy Drugs Market Analysis (2013 2021)
Worldwide Epilepsy Drugs Market Share (2013 2021)
Worldwide Epilepsy Drugs Brand Market Performance (2013 2021)
Epilepsy Drugs Market Major Deal Types
Key Companies Analysis
Key Drivers and Inhibitors of the Epilepsy Drugs Market

Key Epilepsy Drugs Covered in the Report are as follows:

1. Vimpat(Lacosamide)
2. Keppra(Levetiracetam)
3. Briviact(Brivaracetam)
4. Lamictal(Lamotrigine)
5. Neurontin (Gabapentin)
6. Depakine (Sodium Valproate)
7. Sabril (Vigabatrin)
8. Onfi(Clobazam)
9. Fycompa(Perampanel)
10. Inovelon/Banzel(Rufinamide)
11. Zonegran (Zonisamide)
12. Zebinix (Eslicarbazepine Acetate)


Key Companies Covered in the Report are as follows:

1. UCB
2. EISAI
3. Pfizer
4. Sanofi
5. Lundbeck

1. Executive Summary

2. Worldwide – Epilepsy Drugs Market Analysis (2013 – 2021)

3. Worldwide – Epilepsy Drugs Market Share (2013 – 2021)

4. Key Drivers and Inhibitors of the Epilepsy Drugs Market
4.1 Market Drivers
4.2 Inhibitors

5. Worldwide – Epilepsy Drugs Brand Market Performance (2013 – 2021)
5.1 Vimpat(Lacosamide) – UCB
5.2 Keppra(Levetiracetam) – UCB
5.3 Briviact(Brivaracetam) – UCB
5.4 Lamictal(Lamotrigine) – GlaxoSmithKline
5.5 Neurontin (Gabapentin) – Pfizer
5.6 Depakine (Sodium Valproate) – Sanofi
5.7 Sabril (Vigabatrin) – Lundbeck
5.8 Onfi(Clobazam) – Lundbeck
5.9 Fycompa(Perampanel) – EISAI
5.10 Inovelon/Banzel(Rufinamide) – EISAI
5.11 Zonegran (Zonisamide) – EISAI
5.12 Zebinix (Eslicarbazepine Acetate) – EISAI

6. Epilepsy Drugs Market – Major Deal Types
6.1 Epilepsy Drugs Market – Collaboration Deals
6.2 Epilepsy Drugs Market – Licensing Agreement
6.3 Epilepsy Drugs Market – Partnerships Deals

7. Key Companies Analysis
7.1 UCB
7.1.1 Business Overview
7.1.2 Epilepsy Drugs – Latest Development & Trends
7.1 EISAI
7.1.1 Business Overview
7.1.2 Epilepsy Drugs – Latest Development & Trends
7.2 Pfizer
7.2.1 Business Overview
7.2.2 Epilepsy Drugs – Latest Development & Trends
7.3 Sanofi
7.3.1 Business Overview
7.3.2 Epilepsy Drugs – Latest Development & Trends
7.4 Lundbeck
7.4.1 Business Overview
7.4.2 Epilepsy Drugs – Latest Development & Trends


List of Figures

Figure 2–1: Worldwide – Epilepsy Drugs Market (Million US$),2013 – 2016
Figure 2–2: Worldwide – Forecast for Epilepsy Drugs Market (Million US$),2017 – 2021

Figure 5–1: Worldwide – Vimpat Drug Sales (Million US$), 2013 – 2016
Figure 5–2: Worldwide – Forecast for Vimpat Drug Sales (Million US$), 2017 – 2021
Figure 5–3: Worldwide – Keppra Drug Sales (Million US$), 2013 – 2016
Figure 5–4: Worldwide – Forecast for Keppra Drug Sales (Million US$), 2017 – 2021
Figure 5–5: Worldwide – Briviact Drug Sales (Million US$), 2016 – 2021
Figure 5–6: Worldwide – Lamictal Drug Sales (Million US$), 2013 – 2016
Figure 5–7: Worldwide – Forecast for Lamictal Drug Sales (Million US$), 2017 – 2021
Figure 5–8: Worldwide – Neurotin Drug Sales (Million US$), 2013 – 2016
Figure 5–9: Worldwide – Forecast for Neurotin Drug Sales (Million US$), 2017 – 2021
Figure 5–10: Worldwide – Depakine Drug Sales (Million US$), 2013 – 2016
Figure 5–11: Worldwide – Forecast for Depakine Drug Sales (Million US$), 2017 – 2021
Figure 5–12: Worldwide – Sabril Drug Sales (Million US$), 2013 – 2016
Figure 5–13: Worldwide – Forecast for Sabril Drug Sales (Million US$), 2017 – 2021
Figure 5–14: Worldwide – Onfi Drug Sales (Million US$), 2013 – 2016
Figure 5–15: Worldwide – Forecast for Onfi Drug Sales (Million US$), 2017 – 2021
Figure 5–16: Worldwide – Fycompa Drug Sales (Million US$), 2013 – 2016
Figure 5–17: Worldwide – Forecast for Fycompa Drug Sales (Million US$), 2017 – 2021
Figure 5–18: Worldwide – Inovelon/Banzel Drug Sales (Million US$), 2013 – 2016
Figure 5–19: Worldwide – Forecast for Inovelon/Banzel Drug Sales (Million US$), 2017 – 2021
Figure 5–20: Worldwide – Zonegran Drug Sales (Million US$), 2013 – 2016
Figure 5–21: Worldwide – Forecast for Zonegran Drug Sales (Million US$), 2017 – 2021
Figure 5–22: Worldwide – Zebinix Drug Sales (Million US$), 2013 – 2016
Figure 5–23: Worldwide – Forecast for Zebinix Drug Sales (Million US$), 2017 – 2021

List of Tables

Table 3 1: Worldwide – Epilepsy Drugs Market Share(Percent),2013 – 2016
Table 3 2: Worldwide – Forecast for Epilepsy Drugs Market Share(Percent),2017 – 2021

Table 4 1: Epilepsy Branded Drugs Price List(US$),2017

Table 6 1: Collaboration Deals in Epilepsy Drug Market, 2008 – 2017
Table 6 2: Licensing Agreement in Epilepsy Drug Market, 2008 – 2016
Table 6 3: Partnerships Deals in Epilepsy Drug Market, 2008 – 2016

SECONDARY RESEARCH
Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.

PRIMARY RESEARCH
Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.

MARKET ENGINEERING
The market engineering phase involves analyzing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.

EXPERT VALIDATION
The market engineered data is verified and validated by a number of experts, both in-house and external.

REPORT WRITING/ PRESENTATION
After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.

Please Choose License Type

USD $800
USD $1200
USD $1200
Offer

Why Us

  • Why Us In-depth database
    Our Report’s database covers almost all topics of all regions over the Globe..
  • Why Us Recognised publishing sources
    Tie ups with top publishers around the globe.
  • Why Us Customer Support
    Complete pre and post sales support.
  • Why Us Safe & Secure
    Complete secure payment process.